Reverse Mergers

What Inane Nonsense is Cytodyn Hyping Now? (CYDY)

It never seems to stop. Another day, more nonsense from everyone’s favorite reverse merger pink sheet Coronacrapper, Cytodyn (CYDY). So just what is Cytodyn hyping today?

After the bell last night, on the 7th of June, the company issued the latest in a long series of breathless press releases (here) touting, this time, an animal study. Eighteen (18) rhesus macaques were given Cytodyn’s “wonder drug” leronlimab and then deliberately infected with SHIV (aka Monkey AIDS) in an intrarectal challenge (aka up the butt). And what do you know? One of the two doses studied seemed to be effective in preventing the transmission of the Monkey AIDS (hard to say for sure, as there was no control group and n=18 is too small to make valid determinations, but hey, this is CYDY, where it’s all about the press releases to keep American and German retail morons excited). Great news for macaques? Not really. Because just a year ago a study was published on a vaccine that keeps macaques safe from infection by SHIV (here).

But The Nadir won’t tell you about that, because the point of press release is to get the retail base excited about the idea of using leronlimab as “PrEP” (Pre-Exposure Prophylactic) for human AIDS. Currently the approved PrEP regimen is a well known combination pill known as Truvada. Cytodyn is trying to hype up the idea of using a weekly or bi-monthly injection of leronlimab instead. Said The Nadir:

“We are eager to build upon these preclinical results describing leronlimab’s utility in HIV prevention by initiating clinical studies for leronlimab as a PrEP treatment. Current PrEP options require a continued daily dosing regimen in order to be effective and are inherently difficult to maintain in the long-term,” said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn. “Coupled with its safety profile, leronlimab could offer a much needed simple and long-lasting preventative treatment option for people at risk of HIV infection,” concluded Dr. Pourhassan.

It is all just warmed-over nonsense, of course, as The Nadir has been doing this since at least 2013! Remember this press release?

(more…)

Quick Take – Who’s “Distributing” Cytodyn’s “Wonder Drug” Now? (CYDY)

Spolier alert: Actually no-one because Cytodyn does not have any marketable products but if they did….

What a way to start the week, the long awaited “Distribution Agreement” news has finally been released by everyone’s favorite reverse merger pink sheet Coronacrapper, Cytodyn (CYDY).

Readers might recall that on June 2, 2020 The Nadir had this to say:

Distribution-June-2

OK, a non-binding term sheet “with a pretty well known company.” Sounds like absolutely nothing. And on June 11th, The Nadir and Mike Mulholland provided this update:

Cytodyn-distribution-june-11

And now, today July 6th, 2020 we get the big reveal. Just who is lucky enough to “distribute”* Cytodyn’s wonder drug, leronlimab?

CYDY-AmericanRegent

American Regent! Surely a “pretty well known company”. Never heard of them? Prior to 2019 they were known as Luitpold Pharmaceuticals. Never heard of them? Well you might know them from their previous incarnation as Luitpold-Werk. No?

Although the details are few, it appears to be a deal with zero risk for American Regent. Until and unless leronlimab gets an EUA or an approval for Covid-19, there is nothing to distribute. There appear to be no commitment, and American Regent doesn’t get a standard distribution mark-up, they actually get a profit split. The bidding over leronlimab must have been INTENSE.

A quick perusal of the American Regent web site shows they are a distributor of mundane IV vitamin and minerals (31 different SKUs mostly different dosages of a few products) and a few low value generic drugs. (36 SKUs, most just different dosages of a few products).

One thing that DOES make American Regent a perfect partner for Cytodyn, however, is this curious section of their website, devoted to their distribution of products UNapproved by the FDA! Surely a perfect match.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

 

Quick Take – Who’s Grossly Overexaggerating Cytodyn’s TAM Now? (CYDY)

Another day, another relentlessly “optimistic” piece of promotional garbage touting everyone’s favorite Pink Sheet Reverse Merger coronacrapper, Cytodyn (CYDY). Today it is this swill which trumpeted an outlandish TAM (Total Addressable Market) figure that whipped up retail investors on both sides of the Atlantic this morning, before reality began to seep back in. How outlandish? See for yourselves:

Cytodyn TAM (in their dreams)

Yes, $81bn, but that’s not all, maybe even $100bn!

Now for the sobering reality. Cytodyn has exactly zero approved drugs to sell. Zero. After much difficulty they have submitted a BLA to the FDA, to hopefully get their wonder drug, leronlimab, approved in early 2021. Guess that $81bn won’t come this year, if at all.

But even if they get their drug approved, the actual TAM is far far smaller. For you see, dear reader, leronlimab is what is known as a “CCR5 Entry Inhibitor“, and one that must be delivered by IV or injection. There already is a another CCR5 entry inhibitor on the market, known generically as maraviroc, or by its brand name, Selzentry. Unlike the hyped unapproved bullshit from Cytodyn, maraviroc is a convenient pill, available today.

Contrary to anything the long list of promoters, or even The Nadir, might claim, leronlimab is not a new class of medication, it is not a breakthrough, it is just another entry in an existing segment.

And how large is the Total Addressable Market for CCR5 Entry Inhibitors? Currently maraviroc has 100% of that market, and it was, for 2019 a paltry $88mm USD and SHRINKING.

TAM-Chart

Even if leronlimab magically captured 100% market share, $88mm is still only about 7/10ths of a percent of the supposed $12bn HIV TAM. Good luck with that $81bn!

Oh, and coronavirus? If CCR5 entry inhibition had anything to do with Coronavirus, Doctors world-wide would already be using maraviroc. Surprise! They aren’t. 

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

How Can Franklin J. Schaffner’s Masterpiece Help Investors?

From the 29th Scroll, 6th Verse:

“Beware the reverse merger, for it is the devil’s pawn. Alone among listed stocks it exists as shells, or SPACs, or stubs. Yea, it will jump on any trend to excite and possess the masses’ cash. Let them not list in great numbers, for they will make a mockery of exchanges and regulators. Shun them. Drive them back into their bucket shop lairs, for they are the harbingers of massive losses.”

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Quick Take: Who is Getting A Big Raise At Cytodyn Now? (CYDY)

Just a month after selling a multi-million dollar boatload of stock, Coronacrapper Cytodyn (CYDY) CEO Nader “The Nadir” Pourhassan just scored a massive raise.

After the bell last night, Cytodyn issued an 8k (see here) disclosing an almost 100% increase in Nader’s base compensation to $1mm:


He wasn’t doing too badly in prior years either:

Of course on his rambling call with stock promoter Jacob Mestechkin aka Jack Marks yesterday, this was never mentioned. 

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Who’s Suing Cytodyn Now? (CYDY)

Last night a curious 8K (read it here) was filed by flavor-of-the-weak(minded) AIDS-turned-Cancer-turned-Coronacrapper Cytodyn (CYDY). Says the company:

On April 24, 2020, certain stockholders of CytoDyn Inc. (the “Company), including two former directors and a company controlled by a former director (Anthony D. Caracciolo of the Caracciolo Family Trust, Gregory A. Gould, and Alpha Venture Capital Partners L.P., controlled by Carl C. Dockery, respectively), filed a derivative stockholder complaint in the Court of Chancery of the State of Delaware, alleging claims for breach of fiduciary duty and unjust enrichment against the Company’s CEO, current and former CFO, CMO, and current and former members of the Company’s board of directors in connection with certain equity grant awards to these individuals in December 2019 and January 2020. The Company disclosed these awards in the Company’s Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission on December 27, 2019 and February 3, 2020.

There is a lot here to dissect. Firstly, the company is basically being sued by the following people: Anthony Caracciolo, Gregory Gould and Carl Dockery. Who are they?

(more…)

Who’s Touting Cytodyn Now? (CYDY)

Pink sheet retail investor AIDS-turned-Cancer-turned-Coronacrap favorite Cytodyn (CYDY) has been quite the darling of the stuck-at-home newbie trader crowd lately. It seems not a day goes by without some form of stock promotion. And today, 28 April, is no exception.

Presenting an absolute howler of a puff piece on Seeking Alpha, entitled “Finding The Kink In COVID-19’s Armor – Preventing ARDS” by one Theodore Zucconi.

(more…)

Anyone remember Zika Diagnostics, Inc.? – (CODX)

While 2020 is clearly the year of the “Wuhan Flu”, just four years ago, in 2016, a different viral scourge was making headlines. We are discussing, of course, the Zika Virus. Unlike the current Coronavirus pandemic, Zika most certainly attacked children. Most notably crossing the placental barrier and destroying fetal brain tissue in the womb.

The first Zika fatality in the USA occurred in February 2016. As of early March 2016 there were nearly 200 cases in the United States.

In late August 2016, the city of Miami Beach begins closing off some areas to prevent the spread. Tourists, especially pregnant women, are especially worried. Stories of Zika spreading throughout the United States, of being sexually transmitted for months after infection, and more, move like wildfire across the interwebs.

But fear not, a small company with no revenue history, based in Salt Lake City, is ready to ease your fears, and maybe let you get rich at the same time! Introducing Zika Diagnostics, Inc. 

(more…)

RE-UP: Everything Old is New Again: The Continuing Saga of Bioscam Nanoviricides (NNVC)

NOTE: This post has been re-upped because it seems a whole new group of stuck-at-home investors have heard the siren song of this Coronacrapper.

Never one to let an overblown media frenzy over a pandemic scare to go to waste, long-running biocon Nanoviricides (NNVC) is back.

Read the backstory from 2014 on this scam, here, in a great piece by Duff McDonald in the New York Observer. Check out some of our notes here and here, and an amazing expose of NNVC and CTIX/IPIX‘s Krishna Menon here.

(more…)

Quick Take – Well Done Abeona (ABEO)

Today is a very special day friends, it marks an all time low for Steve Rouhandeh and Mark Ahn‘s reverse merger mega stinker Abeona Therapeutics (ABEO).

Steve, a well known stock promoter (see this great piece by Aaron Elstein here) somehow transitioned from hawking dot-bombs to bio-turds. Mark Ahn of Galena infamy hardly needs an introduction.

For those unfamiliar with their latest sinkhole, Abeona started life way back in 1974 as Chemex Corporation. In 1983 it became Chemex Pharmaceuticals. In 1996 it became Access Pharmaceuticals. In 2014 it became PlasmaTech Biopharmaceuticals, In 2015 it finally became Abeona. Here’s a stock chart going back as far as Bloomberg has data:

Abeo-LongTerm

Please note the all time low, $1.89 is today (23 August 2019), the all-time high was $218,000 back in 1981. That is impressive value destruction. Well done SCO (and Mark).

Always remember Maxim 1: ALL REVERSE MERGERS ARE SCAMS. ALL OF THEM. EVERY SINGLE ONE. IN ONE WAY OR ANOTHER.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.